SCANNON PATRICK J.,FELDSTEIN JEFFREY D.,SOLINGER ALAN M.
申请号：
NZ59702410
公开号：
NZ597024A
申请日:
2010.05.28
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
NZ 597024 Disclosed is the use of an anti-IL-1&bgr； binding antibody or binding fragment thereof in the manufacture of a medicament for reducing a cardiovascular event in a subject, wherein the subject is a subject with a history of a previous cardiovascular event or a history of at least one risk factor for cardiovascular disease, and wherein the cardiovascular event is myocardial infarction, stroke, cardiovascular death, congestive heart failure, cardiac arrest, acute coronary syndrome, angina, or a revascularization procedure. Also disclosed is the use of an anti-IL-1&bgr； binding antibody or binding fragment thereof in the manufacture of a medicament for reducing mortality following a cardiovascular event in a subject.
